Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 19, 2025
Daily News
May 19, 2025
- Impact of US Drug Policy: President Trump Shaking the World of Pharma
May 19, 2025
- Japan’s Big 4 Wholesalers Log Operating Margin of 1.24%, All Break 1% Mark: Tally
May 19, 2025
- At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
- Sawai Wins Lawsuit over CML Use in Sprycel Generic
May 19, 2025
- Boehringer Ingelheim, Kanagawa Join Hands in Disease Prevention
May 19, 2025
- AstraZeneca, Nara City Form Partnership in NCDs
May 19, 2025
- Seikagaku Eyes FDA Re-Filing of Herniated Disk Drug within 1 Year
May 19, 2025
- PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
May 19, 2025
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…